Patents Issued in August 15, 2019
-
Publication number: 20190247446Abstract: Ammonia oxidizing microorganism preparations for delivery to the gastrointestinal system, kits including ammonia oxidizing preparations for delivery to the gastrointestinal system, and devices for administering ammonia oxidizing preparations to the gastrointestinal system are provided. Methods of introducing ammonia oxidizing microorganisms to the gastrointestinal system are provided. Methods of treating disorders, including gastrointestinal disorders and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.Type: ApplicationFiled: July 18, 2017Publication date: August 15, 2019Inventors: David R. Whitlock, Larry Weiss, Lauren Nicole Ambrogio
-
Publication number: 20190247447Abstract: Compositions and methods of treating a gastrointestinal dysbiosis using a limited number of defined bacterial species are provided.Type: ApplicationFiled: November 23, 2016Publication date: August 15, 2019Inventors: Julie BUTTON, David COOK, Matthew HENN, Mary-Jane Lombardo MCKENZIE, Kevin LITCOFSKY, Asuncion MARTINEZ, Gregory MCKENZIE, Madhumitha NANDAKUMAR, Marin VULIC, Jennifer WORTMAN
-
Publication number: 20190247448Abstract: The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.Type: ApplicationFiled: January 16, 2019Publication date: August 15, 2019Inventors: George GRANT, Angela Margaret PATTERSON, Imke MULDER, Seanin MCCLUSKEY, Emma RAFTIS
-
Publication number: 20190247449Abstract: The present invention is directed to a method for preventing and/or treating infection of plant or animal host species by fungal, bacterial and/or viral pathogens, wherein said method comprises the steps of providing a mixture of one or more non-pathogenic bacteria and one or more activating agents; and administering said mixture to said host species. The invention also encompasses compositions comprising a mixture of non-pathogenic bacteria and one or more activating agents.Type: ApplicationFiled: September 13, 2017Publication date: August 15, 2019Inventors: Amit AVIDOV, Avner BARAZANI, Mor ZEILKHA
-
Publication number: 20190247450Abstract: Provided is an agent or a food or drink for inhibiting the onset of overall disease. An agent for inhibiting a decrease in a disease-free rate comprises a lactic acid bacterium as an active ingredient.Type: ApplicationFiled: October 30, 2017Publication date: August 15, 2019Applicants: KABUSHIKI KAISHA YAKULT HONSHA, TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGYInventors: Yukitoshi AOYAGI, Satoshi MATSUBARA, Yusuke HONDA, Ryuta AMAMOTO, Koji MIYAZAKI
-
Publication number: 20190247451Abstract: An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.Type: ApplicationFiled: June 22, 2017Publication date: August 15, 2019Inventors: Nancy TAWIL, Edwige Caroline Rebecca ARNOLD
-
Publication number: 20190247452Abstract: A conditionally replicating adenovirus were generated that can specifically replicate and express therapeutic genes in neuroendocrine tumors. The promoter-specific expression of the adenoviruses is regulated upstream by an INSM1 (insulinoma-associated-1) promoter that is silent in normal adult tissues but active in developing neuroendocrine cells and neuroendocrine tumors. By placing the INSM1-promoter with an insulator and two copies of neuronal restrictive silencer elements in an adenoviral vector, the construct can retain tumor specificity and drive expression of a mutated adenovirus E1A gene (424E1A) and the herpes simplex virus thymidine kinase gene. The INSM1-promoter-driven viruses could replicate specifically in the INSM1-positive cells and I NSM1-specific HSV-tk expression in combination with ganciclovir treatment displayed dose-dependent tumor cell-specific killing in insulinomas.Type: ApplicationFiled: October 28, 2016Publication date: August 15, 2019Inventors: Michael Lan, Mary Breslin
-
Publication number: 20190247453Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent, along with other moieties that seem to be enhanced or bioavailability of increased by the same. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art. Construction of the transdermal patch of reservoir type is also taught, which enables things such as Vitamin B12 to become part of the complex deliverable by the inventions.Type: ApplicationFiled: April 29, 2019Publication date: August 15, 2019Inventor: Ludwig Weimann
-
Publication number: 20190247454Abstract: The present invention provides compositions comprising optimized ratios of Red clover phytoestrogens as determined by a proprietary physiologically based pharmacokinetic and pharmacodynamic model. The compositions are useful for modulating, preventing or treating postmenopausal or climacteric symptoms, which include but are not limited to bone loss, bone remodeling, hot flushes and vaginal atrophy. The present invention also provides methods for modulating, preventing or treating postmenopausal or climacteric symptoms using the compositions disclosed herein.Type: ApplicationFiled: April 5, 2019Publication date: August 15, 2019Inventors: Yun Kau TAM, Yi-Chan James LIN, Brian Duff SLOLEY, Chih-Yuan TSENG
-
Publication number: 20190247455Abstract: A hybrid herbal and drug composition includes an amount of Chinese herb about 0.01 to 5% by weight of the composition; an amount of animal-based matter about 0.01 to 5% by weight of the composition; an amount of vitamin about 0.01 to 5% by weight of the composition; an amount of mineral about 0.01 to 5% by weight of the composition; an amount of hormone about 0.01 to 5% by weight of the composition; an amount of factory produced product about 0.01 to 5% by weight of the composition; and an amount of the purified water about 70% to 99.94% by weight of the composition.Type: ApplicationFiled: February 14, 2019Publication date: August 15, 2019Inventor: Shui Yin Lo
-
Publication number: 20190247456Abstract: The invention relates to the field of traditional Chinese medicine, in particular to provides traditional Chinese medicine compositions for the treatment of psoriasis, their preparations and their preparation methods. The Chinese medicine compositions of the invention are consisted of 20-80 parts of Rumex madaio, 20-80 parts of Radix sophora flavescens, 10-50 parts of Herba Siphonostegiae, 10-40 parts of Chinese pulsatilla chinensis, and 5-30 parts of Acacia catechu, by weight. The invention also includes the preparation methods of the traditional Chinese medicine compositions and the preparations containing the traditional Chinese medicine compositions and method for preparing the same.Type: ApplicationFiled: September 27, 2016Publication date: August 15, 2019Inventors: Siju ZHANG, Jinhua WANG, Wenjie QIN, Xiaoning YANG, Juanjuan LIANG, Hongjiang HAO, Hongyu WANG
-
Publication number: 20190247457Abstract: The present invention provides a Plexin-binding regulating agent containing a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt of the cyclic peptide.Type: ApplicationFiled: June 16, 2017Publication date: August 15, 2019Inventors: Hiroaki Suga, Nasir Kato Bashiruddin, Junichi Takagi, Yukiko Matsunaga
-
Publication number: 20190247458Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.Type: ApplicationFiled: April 25, 2019Publication date: August 15, 2019Inventors: Terrence Norchi, Steven Kates, Rutledge Ellis-Behnke
-
Publication number: 20190247459Abstract: This invention relates to compositions including antibacterial compounds. The invention also relates to the use of the compositions in methods of treating bacterial infections. In one aspect the present invention also provides a method of increasing the susceptibility of bacteria to the anti-bacterial activity of a compound, the method comprising contacting the bacteria with a star shaped peptide polymer of the invention, thereby increasing the susceptibility of the bacteria to the anti-bacterial activity of the compound. Preferably, the method further includes the step of contacting the bacteria with the compound for which the bacteria have increased susceptibility to. The invention is further relates to the combination of a star shaped peptide polymer and an anti-bacterial compound that restore the sensitivity of antibiotic resistant bacteria to antibiotics that are otherwise ineffective when administered alone.Type: ApplicationFiled: November 2, 2017Publication date: August 15, 2019Inventors: Greg GuangHua Qiao, Neil Martin O'Brien-Simpson, Shu Jie Lam, Eric Charles Reynolds
-
Publication number: 20190247460Abstract: The present disclosure provides molecules which modulate cell growth. These molecules include those that bind sialic acid which may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.Type: ApplicationFiled: September 20, 2017Publication date: August 15, 2019Inventors: Helen Connaris, Judith Telford, Graeme Rogers
-
Publication number: 20190247461Abstract: The present invention relates to the use of a homeoprotein or a recombinant vector encoding said protein for treating or preventing DNA damage and/or cellular aging. In particular, the invention concerns the use of Engrailed for the treatment of Parkinson disease.Type: ApplicationFiled: September 23, 2016Publication date: August 15, 2019Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COLLEGE DE FRANCE, SORBONNE UNIVERSITEInventor: Alain Prochiantz
-
Publication number: 20190247462Abstract: The inventors have determined that increasing the expression level or activity of FKBP-L polypeptide in a subject, which can be provided by expression of nucleic acids encoding FKBP-L or by providing FKBP-L polypeptides to a subject is advantageous for use in the treatment of obesity and obesity-related disorders. In particular increased expression or activity of FKBP-L polypeptide in a subject may be used to treat excessive weight gain (which can be characterised as obesity), glucose intolerance, diabetes and metabolic syndrome, which are closely linked to obesity and insulin resistance. FKBP-L can also be used as a biomarker for obesity and obesity-related disorders.Type: ApplicationFiled: October 18, 2017Publication date: August 15, 2019Applicant: The Queen's University of BelfastInventors: Tracy ROBSON, David GRIEVE, Amy SHORT, Adrien KISSENPFENG, Marie MIGAUD, Rachel BENNETT, Anita YAKKUNDI, Helen MCCARTHY
-
Publication number: 20190247463Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: ApplicationFiled: April 29, 2019Publication date: August 15, 2019Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: George D. YANCOPOULOS
-
Publication number: 20190247464Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.Type: ApplicationFiled: April 24, 2019Publication date: August 15, 2019Applicant: Hadasit Medical Research Services and Development Ltd.Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
-
Publication number: 20190247465Abstract: The present invention relates to an immunomodulator for the prevention or treatment of an allergic disease caused by house dust mite-derived allergens. Particularly, the present invention provides an immunomodulatory pharmaceutical composition comprising as an effective ingredient a bacteria extracellular vesicle containing an allergens derived from North American house dust mite or European house dust mite, and a preparation method therefor.Type: ApplicationFiled: November 4, 2016Publication date: August 15, 2019Inventors: Young Koo JEE, Yoon-Keun KIM, Hanki PARK
-
Publication number: 20190247466Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.Type: ApplicationFiled: March 7, 2017Publication date: August 15, 2019Applicants: UNIVERSITAT ZURICH, UNIVERSITAT BASELInventors: Osiris MARROQUIN BELAUNZARAN, Ulf PETRAUSCH, Christoph RENNER
-
Publication number: 20190247467Abstract: The disclosure relates to the use of variants of C-type natriuretic peptide (CNP) to treat osteoarthritis, to ameliorate one or more symptoms of osteoarthritis, and to treat disorders having an osteoarthritis component.Type: ApplicationFiled: December 8, 2016Publication date: August 15, 2019Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: CHARLES A. O'NEILL, TODD M. OPPENEER, JASON K. PINKSTAFF
-
Publication number: 20190247468Abstract: This disclosure provides a composition containing a conjugate with a modified insulin molecule. The conjugate has an insulin molecule, which can be insulin or an insulin analog, glucagon, GLP-1, GLP-2 or a GLP-1 agonist. The conjugate also contains one or more polymers. Each of the one or more polymers is covalently linked to the insulin molecule. Additionally, each of the one or more polymers is covalently linked to between 0 to 50 copies of a decoy ligand, and to between 0 to 50 copies of a glucose-binding agent, such that the combined total number of glucose-binding agents and decoy ligands covalently linked to each of the one or more polymers is at least 1. The conjugate can reversibly bind to soluble glucose and in which the extent of its glucose-binding controls the extent to which the modified insulin is able to bind to and activate the insulin receptor. Methods of making the conjugate, as well as use of the conjugate in treatment, are also provided.Type: ApplicationFiled: May 6, 2016Publication date: August 15, 2019Inventor: Alborz MAHDAVI
-
Publication number: 20190247469Abstract: The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.Type: ApplicationFiled: July 6, 2017Publication date: August 15, 2019Applicant: Building Block Nutritionals, LLCInventors: James McGrath, Paul Manning, Eugene Scavola
-
Publication number: 20190247470Abstract: A method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy. A pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector. Pharmaceutical compositions including at least one isolated nucleic acid sequence encoding at least one TALEN, at least one ZFN, and gene editing composition of C2c1, C2c3, TevCas9, Archaea Cas9, CasY.1-CasY.Type: ApplicationFiled: April 29, 2019Publication date: August 15, 2019Applicants: Excision Bio Therapeutics, Inc., Temple University of the Commonwealth System of Higher EducationInventors: Kamel Khalili, Thomas Malcolm, Kenneth I. Kohn
-
Publication number: 20190247471Abstract: Pharmaceutical composition containing a mixture of proenzymes and enzymes, containing proenzymes trypsinogen and chymotrypsinogen and enzymes ?-amylase and lipase as active substances, and one or more pharmaceutically acceptable excipients, for simultaneous, separate and subsequent administration of the composition in parenteral or transmucosal way, the composition has anti-proliferative and anti-metastatic effects to cancer tumours and is intended for therapeutic, prophylactic and anti-metastatic use in mammals.Type: ApplicationFiled: February 21, 2019Publication date: August 15, 2019Inventors: Frantisek TRNKA, Pavel DOLEZAL
-
Publication number: 20190247472Abstract: The present invention relates to the use of plasminogen in the dissolution of fresh and old thrombus. Compared with other existing thrombolytic drugs, the plasminogen of the present invention can specifically dissolve thrombus without causing side effects such as bleeding. The drug of the present invention also has the advantages of dissolving both fresh and old thrombus, with a long half-life and controllable thrombolytic strength. Therefore, plasminogen may become a brand-new strategy for dissolving thrombus in vivo.Type: ApplicationFiled: December 16, 2016Publication date: August 15, 2019Inventor: Jinan LI
-
Publication number: 20190247473Abstract: An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.Type: ApplicationFiled: April 26, 2019Publication date: August 15, 2019Inventors: George Shlieout, Claus-Juergen Koelln, Frithjof Sczesny, Jens Onken, Andreas Koerner
-
Publication number: 20190247474Abstract: The present invention is directed to hemostatic compositions comprising at least partially integrated agglomerated ORC fibers, fibrinogen, and thrombin and methods of forming a powdered hemostatic composition, comprising the steps of: forming a suspension of a mixture comprising particles of fibrinogen, thrombin, ORC fibers in a non-aqueous low boiling solvent, agitating and shearing said suspension in a high shear mixing reactor, adding water to allow particles to agglomerate, allowing the non-aqueous solvent to evaporate, drying and sieving the composition; and thus forming the powdered hemostatic composition.Type: ApplicationFiled: February 13, 2018Publication date: August 15, 2019Inventors: Shuang Chen, Yufu Li, Aibin Yu, Jianping Yu
-
Publication number: 20190247475Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.Type: ApplicationFiled: February 14, 2019Publication date: August 15, 2019Applicants: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
-
Publication number: 20190247476Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof; and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose and sucrose.Type: ApplicationFiled: September 13, 2017Publication date: August 15, 2019Applicant: Allergan, Inc.Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
-
Publication number: 20190247477Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.Type: ApplicationFiled: February 21, 2019Publication date: August 15, 2019Applicant: Dyax Corp.Inventors: Robert Charles Ladner, Arthur Charles Ley, Shirish Hirani, Anthony Williams
-
Publication number: 20190247478Abstract: The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.Type: ApplicationFiled: October 17, 2017Publication date: August 15, 2019Inventors: Stephen TOMLINSON, DeAnna ADKINS, Ali ALAWIEH
-
Publication number: 20190247479Abstract: Described herein are compositions and methods for treating cancer through the combination of tumor antigen-pulsed dendritic cells and Dengue Virus. The combination of the two forms of therapeutic intervention provides enhanced tumor cell reduction compared to either alone. The cancer targeted by compositions and methods described herein may be a solid cancer or blood cancer.Type: ApplicationFiled: April 19, 2019Publication date: August 15, 2019Inventor: Bruce W. LYDAY
-
Publication number: 20190247480Abstract: The present invention relates generally to the field of prophylaxis and therapy of metastatic cancer. In particular there is provided a protein; Ras Homology gene family, member C (RhoC) or peptide fragments thereof that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to use of RhoC or peptides derived thereof or RhoC specific T-cells for treatment of metastatic cancer. Hence, the invention in one aspect relates to RhoC specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. Also the use of RhoC and immunogenic peptide fragments hereof in cancer treatment, diagnosis and prognosis is provided.Type: ApplicationFiled: April 19, 2019Publication date: August 15, 2019Inventors: Mads Hald Andersen, Per Thor Straten
-
Publication number: 20190247481Abstract: Contemplated compositions and methods counteract evasive measures of a tumor by rendering access to the tumor microenvironment, tagging the tumor microenvironment with chemoattractant and/or cytokines, delivering or facilitating a cell-based therapy in the tumor microenvironment while providing inhibition of immune suppressor cells in the tumor microenvironment.Type: ApplicationFiled: April 26, 2019Publication date: August 15, 2019Inventor: Patrick SOON-SHIONG
-
Publication number: 20190247482Abstract: A polypeptide for use in medicine is provided. The polypeptide is administered simultaneously, separately or sequentially with an immune checkpoint inhibitor. The polypeptide comprises at least one polypeptide comprising a region of at least 12 amino acids of a self-antigen or a sequence having at least 80% identity to the region. The polypeptide is less than 100 amino acids in length.Type: ApplicationFiled: June 2, 2017Publication date: August 15, 2019Inventors: Gustav Gaudernack, Audun Tornes
-
Publication number: 20190247483Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.Type: ApplicationFiled: April 24, 2019Publication date: August 15, 2019Applicant: GenVec, Inc.Inventors: Ping Chen, Duncan McVey, Douglas E. Brough, Joseph Bruder
-
Publication number: 20190247484Abstract: The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.Type: ApplicationFiled: January 31, 2019Publication date: August 15, 2019Inventors: Harold David Gunn, Salim Dhanji, David W. Mullins
-
Publication number: 20190247485Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof; comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DIVEF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.Type: ApplicationFiled: April 23, 2019Publication date: August 15, 2019Applicant: Biogen MA Inc.Inventor: Vissia Viglietta
-
Publication number: 20190247486Abstract: Provided is a recombinant P particle formed from a norovirus capsid P protein of a chimeric A?1-m peptide (m being an integer ranging from 6 to 15), wherein the recombinant P particles form an ordered and repetitive antigen array. Also provided are a nucleotide sequence encoding the recombinant P particle, a pharmaceutical composition comprising same and a use thereof for preparing a medicament for treating or preventing Alzheimer's disease. Also provided is a method for preparing the recombinant P particle.Type: ApplicationFiled: June 29, 2016Publication date: August 15, 2019Inventors: Wei KONG, Hui WU, Chunlai JIANG, Xianghui YU, Lu FU, Yingnan LI
-
Publication number: 20190247487Abstract: The present invention relates to a recombinant vaccinia virus in which the expression of some genes is inhibited, and a use thereof. The recombinant vaccinia virus of the present invention selectively kills cancer cells, and has an excellent reproducibility in cancer cells. Also, the virus has a lower toxicity to normal cells, and thus has an advantage of being safe for a human body. Therefore, the recombinant vaccinia virus of the present invention can be effectively used as a composition for treating cancer.Type: ApplicationFiled: July 21, 2017Publication date: August 15, 2019Applicant: KOLON LIFE SCIENCE, INC.Inventors: Sujeong KIM, Minjung KIM, Heonsik CHOI, Jaeil SHIN, Minju KIM, Hyesun LEE, Soondong LEE, Hwanjun CHOI, Joonsung KIM, Jieun HONG, Eunjin LEE
-
Publication number: 20190247488Abstract: This invention relates to Virus-Like Particles (VLPs) derived from Enterovirus and vaccines comprising such VLPs which elicit immune responses and/or protective neutralizing antibody responses directed against an Enterovirus. The instant invention provides expression cassettes and methods for making Enterovirus CV-A16 VLPs and compositions enriched in CV-A16 VLPs which exhibit conformational epitopes which elicit immune responses and/or neutralizing antibody responses which may be used in vaccines directed against Enterovirus CV-A16.Type: ApplicationFiled: September 21, 2017Publication date: August 15, 2019Inventor: Mary Jane CARDOSA
-
Publication number: 20190247489Abstract: The influenza B strain is epidemiologically relevant in the pediatric population. Immunogenic priming of children with influenza B vaccine adjuvanted with an oil-in-water emulsion primes an immune response to a booster vaccine comprising influenza B virus antigen from a differing strain or lineage, irrespective of whether the booster comprises an adjuvant.Type: ApplicationFiled: November 16, 2018Publication date: August 15, 2019Inventor: Theodore TSAI
-
Publication number: 20190247490Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.Type: ApplicationFiled: April 17, 2019Publication date: August 15, 2019Applicant: Phibro Animal Health CorporationInventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
-
Publication number: 20190247491Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.Type: ApplicationFiled: April 16, 2019Publication date: August 15, 2019Inventors: Frank TOMAKA, Maria Grazia PAU, Johanna SCHUITEMAKER, Dan BAROUCH, Jintanat ANANWORANICH, Merlin ROBB, Nelson L. MICHAEL, Jerome KIM
-
Publication number: 20190247492Abstract: The present invention relates to a vaccine composition comprising a multimeric complex of Herpes Simplex Virus (HSV) polypeptides for the treatment or vaccination against HSV. The present invention also relates to a vector comprising a polynucleotide encoding the HSV polypeptides and a host cell comprising the vector. The present invention further comprises a method for producing the vaccine composition.Type: ApplicationFiled: March 14, 2017Publication date: August 15, 2019Inventors: Garyfalia STERGIOU, Christian SCHAUB, Corinne JOHN
-
Publication number: 20190247493Abstract: Provided herein are genetically modified arenaviral vectors suitable as vaccines for prevention and treatment of cytomegalovirus infections and reactivation. Also provided herein are pharmaceutical compositions and methods for the treatment of cytomegalovirus infections and reactivation. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of treating cytomegalovirus infections and reactivation.Type: ApplicationFiled: September 20, 2018Publication date: August 15, 2019Inventors: Klaus Orlinger, Karen Lingnau, Thomas Monath, Farshad Guirakhoo, Gerhard Fuhrmann, Katherine Cohen, Vera Baumgartl-Strasser, Andreas Aspöck, Manuela Kainer, Bernhard Brim, Bettina Kiefmann, Elizabeth Watson, Mario Aistleithner, Katharina Bayer, Elsa Mühlbacher
-
Publication number: 20190247494Abstract: The invention relates to a polypeptide carrier for presenting a target polypeptide, and use thereof. In particular, the invention relates to a nucleic acid molecule, comprising a nucleotide sequence encoding a polypeptide carrier, and being used for insertion of a nucleotide sequence encoding a target polypeptide. In addition, the invention further relates to a recombinant protein comprising the polypeptide carrier and a target polypeptide. Furthermore, the invention further relates to use of the nucleic acid molecule and the recombinant protein. In addition, the invention further relates to a vaccine or a pharmaceutical composition useful for preventing, alleviating or treating HBV infection or a disease associated with HBV infection (e.g., hepatitis B), comprising a recombinant protein comprising the polypeptide carrier of the invention and an epitope from HBV.Type: ApplicationFiled: August 24, 2016Publication date: August 15, 2019Applicants: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY, LTD.Inventors: Tianying ZHANG, Quan YUAN, Xueran GUO, Ying ZHANG, Qinjian ZHAO, Jun ZHANG, Ningshao XIA
-
Publication number: 20190247495Abstract: Described herein are compounds for use in vaccine compositions which contain natural or synthetic carbohydrate antigens. Such vaccines may be highly immunologically active due to the conjugation with an immune-stimulating protein or with a monophosphorylated lipid A derivative, and may be self-adjuvanting due to the presence of a monophosphorylated lipid A derivative. Treatments for cancer and fungal and bacterial infections are described herein.Type: ApplicationFiled: February 20, 2019Publication date: August 15, 2019Inventors: Zhongwu Guo, Guochao Liao, Zhifang Zhou, Mohabul Mondal, Srinivas Burgula